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httpcense.Abstract Background/aim: Autoimmunity is a disease in which the immune system mistakenly
attacks the body’s own cells and tissues. Sometimes the whole body is attacked, and sometimes only
one organ.
The aim of the work: The aim of this study was to evaluate antinuclear and anti smooth muscle
antibodies, two common markers of autoimmunity, in COPD and their relation with different com-
ponents of the disease and disease severity.
Methods: The study included 50 clinically stable COPD patients classiﬁed into two groups mild
to moderate (group A) and severe to very severe (group B) according to GOLD (2009) [13] criteria
plus 30 healthy control subjects (15 smokers and 15 non smokers). Blood levels of ANA and ASMA
(measured by ELISA) were recorded.
Results: Levels of both ANA and ASMA were signiﬁcantly higher in patients than in controls as
a whole group but smoker controls showed signiﬁcantly higher levels of both antibodies than mild
to moderate COPD group (group A) indicating that not only smoking is responsible for COPD but
other factors also play a role. Also high levels of these antibodies in smoker controls than in non
smokers indicate a role of smoking in their development which is augmented by the direct relation
with smoking index both in patients and controls.
Conclusion: Both ANA and ASMA levels are elevated in COPD patients compared to controls
(smokers and non smokers) and levels elevated in healthy smokers compared to group A COPD
patients. Autoimmunity plays a role in the pathogenesis of COPD.
ª 2014 Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest Diseases and
Tuberculosis.Open access under CC BY-NC-ND license.m (T.S. Essawy).
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An enhanced and persistent inﬂammatory response to the
inhalation of particles and gases, mostly tobacco smoking,
is considered a key pathogenic mechanism of chronic
obstructive pulmonary disease (COPD) [7]. Recent reports
claim that autoimmunity might play a role in the pathogen-he Egyptian Society of Chest Diseases and Tuberculosis.
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50 T.M. Gouda et al.esis of the disease [21]. Many auto antibodies were found to
be elevated in COPD including anti elastin antibody and
auto antibodies against pulmonary epithelial and endothelial
cells [10].
Antinuclear (ANA) and anti-smooth muscle antibodies are
two important markers of autoimmunity which can be easily
and accurately assessed [12].Subjects and methods
Study design
Prospective case control study.
Subjects
This study was performed on 80 subjects, 50 patients were
clinically stable COPD patients from those attending the
Chest Department at Banha University Hospitals in the
period between August 2011 and April 2012 plus 30 age
matched apparently healthy control subjects, 15 smokers
and 15 non smokers, selected from volunteers and patients
relatives.Inclusion criteria
Patients with COPD diagnosed according to [13] criteria.
Exclusion criteria (due to possible effects on lung function and/
or antibody levels)
 Patients with pneumonectomy, lung cancers [11].
 Patients with residual extensive tuberculous lesion or active
disease [24].
 Patients with diabetes mellitus, collagen vascular disorders
[25].
 Patients with renal and hepatic disorders and those on sys-
temic anti inﬂammatory therapy [18].
Patients and controls were classiﬁed into four groups
 Group (A): Twenty-ﬁve, COPD patients grade I and II
(FEV1 > 50%).
 Group (B): Twenty-ﬁve, COPD patients grade III and IV
(FEV1 < 49%).
 Group (C): Fifteen healthy current cigeratte smoker sub-
jects (positive controls).
 Group (D): Fifteen healthy never smoker subjects (negative
control).
All subjects were submitted to the following:
1. History taking with the stress on:
 History of smoking (types and smoking index) [9].
 History of chest symptoms (cough, expectoration, dyspnea
and wheeze).
 History of any other co-morbidities that may raise the anti
nuclear and anti smooth muscle antibodies as diabetes mel-
litus, tuberculosis, hepatic disease, renal disease, and colla-
gen vascular diseases [25].2. Clinical examination both general and local.
3. Body mass index (BMI) was calculated as the weight in
kg divided by height2.
4. Complete blood count, liver function tests, kidney func-
tion tests and erythrocyte sedimentation rate to conﬁrm inclu-
sion and exclusion criteria.
5. Radiological examination: Plain X-ray chest P-A view.
6. Pulmonary function tests (spirometry) before and after
broncho dilatation.
7. Anti nuclear antibody measurement (Von Muhlen and
Tan [29])
 Samples
This procedure was performed on a serum specimen. Addi-
tion of azide or other preservatives to the test samples was
avoided as it may adversely affect the results. Grossly hemo-
lyzed or lipemic serum or specimens were also avoided.
Samples were preserved at 20 C till all samples were col-
lected and then analyzed. Specimens were also mixed well after
thawing and prior to testing.
 Principles of the Procedure
Highly puriﬁed individual antigens plus extracts from HEp-
2 nuclei and nucleoli are bound to the surface of a microwell
plate. The antigens include chromatin (dsDNA and histones),
Sm/RNP, SS-A, SS-B, Scl-70, centromere, PCNA, Jo-1, mito-
chondria (M-2) and ribosomal-P protein, as well as the ex-
tracts. Anti-chromatin reactivity has recently been shown to
be both a sensitive and early marker for SLE. Pre-diluted con-
trols and diluted patient sera are added to separate wells,
allowing any ANA antibodies present to bind to the immobi-
lized antigen. Unbound sample is washed away and an enzyme
labeled anti-human IgG conjugate is added to each well. A sec-
ond incubation allows the enzyme labeled anti-human IgG to
bind to any patient antibodies, which have become attached to
the microwells. After washing away any unbound enzyme la-
beled anti-human IgG, the remaining enzyme activity is mea-
sured by adding a chromogenic substrate and measuring the
intensity of the color that develops. The assay can be evaluated
spectrophotometrically by measuring and comparing the color
intensity that develops in the patient wells with the color in the
control wells.
 Calculation of Results
The average Optical Density (OD) for each set of duplicates
is ﬁrst determined. The reactivity for each sample can then be
calculated by dividing the average OD of the sample by the
average OD of the ANA ELISA Low Positive. The result is
multiplied by the number of units assigned to the ANA ELISA
Low Positive found on the label.
Sample Value ¼ Sample OD
Positive
ANA ELISA Low
ANA ELISA Low Positive OD (units)
Reactivity is related to the quantity of antibody present in a
non-linear fashion. While increases and decreases in patient
antibody concentrations will be reﬂected in a corresponding
rise or fall in reactivity, the change is not proportional (i.e. a
doubling of the antibody concentration will not double the
Study of anti nuclear and anti smooth muscle antibodies 51reactivity). For more accurate quantitation of patient anti-
body, serial dilutions of the patient sample were run and the
last dilution to measure positive in the assay should be re-
ported as the patient’s antibody titer.
 Interpretation of Results
The ELISA assay is very sensitive to technique and is capa-
ble of detecting even small differences in patient populations.
The sample can then be classiﬁed as negative, moderate po-
sitive or strong positive according to the manufacturer’s refer-
ence shown below.
Units/ml
Negative <20
Moderate positive 20–60
Strong positive >601. A positive result indicates the presence of ANA antibod-
ies and suggests the possibility of autoimmunity.
2. A negative result indicates none of the anitbobies tested
for are present or are below the levels of the negative cut-off
for the assay.
8. Anti smooth muscle anti body (Actin IgG) measurement
[2]
 Sampling
The same sample as ANA.
 Principles of the Procedure
Puriﬁed F-actin antigen is bound to the wells of a polysty-
rene microwell plate under conditions that will preserve the
antigen in its native state. Pre-diluted controls and diluted pa-
tient sera are added to separate wells, allowing any actin anti-
bodies present to bind to the immobilized antigen. Unbound
sample is washed away and an enzyme labeled anti-human
IgG conjugate is added to each well. A second incubation al-
lows the enzyme labeled anti-human IgG to bind to any pa-
tient antibodies, which have become attached to the
microwells. After washing away any unbound enzyme labeled
anti-human IgG, the remaining enzyme activity is measured by
adding a chromogenic substrate and measuring the intensity of
the color that develops. The assay can be evaluated spectro-
photometrically by measuring and comparing the color inten-
sity that develops in the patient wells with the color in the
control wells.
 Calculation of Results
The average OD for each set of duplicates is ﬁrst deter-
mined. The reactivity for each sample was then calculated by
dividing the average OD of the sample by the average OD of
the Actin ELISA low positive.
The result is multiplied by the number of units assigned to
the Actin ELISA Low Positive found on the label.
Sample Value ¼ Sample OD
Positive
Actin ELISA LowActin ELISA Low Positive OD (units)
Reactivity is related to the quantity of antibody present in a
non-linear fashion. While increases and decreases in patient
antibody concentrations will be reﬂected in a corresponding
rise or fall in reactivity, the change is not proportional (i.e. a
doubling of the antibody concentration will not double the
reactivity). For more accurate quantitation of patient antibody
is required, serial dilutions of the patient sample run and the
last dilution to measure positive in the assay should be re-
ported as the patient’s antibody titer.
 Interpretation of Results
Units/ml
Negative < 20
Weak Positive 20–30
Moderate to Strong Positive >301. A positive result indicates the presence of Actin antibodies
and suggests the possibility of an autoimmune disease.
2. A negative result indicates no Actin antibody or levels
below the negative cut-off of the assay.
Results
Table 1 shows that 28% of group A were in clinical stage I, 72%
in clinical stage II, 72% of group B in clinical stage III and 28%
in clinical stage IV and that was statistically signiﬁcant. The
table also shows that 56% of group A were <60 years old while
44% were >60 years. In group B 68% were <60 years old
while 32% were >60 years old. 86.7% of group C and 100%
of group D were <60 years old only 13.3% of group C were
>60 years old and that was statistically signiﬁcant. Females
were not found except in group D (66.7%) and the main pre-
senting symptoms in patients is dyspnea (64%) and cough
(36%) and that was statistically non signiﬁcant. SI and
FEV1%, FEF25–75% between 4 groups were statistically signif-
icant while BMI was not statistically signiﬁcant.
Table 2 shows that group B patients have a smoking index
signiﬁcantly higher than both group A and healthy smokers.
Healthy smokers have a smoking index signiﬁcantly higher
than group A patients.
Table 3 shows that both ANA and ASMA levels were sig-
niﬁcantly higher in group B than in group A patients.
Table 4 shows a signiﬁcant negative correlation between
both ANA and ASMA levels and post bronchodilator
FEV1% in the whole COPD groups.
Table 5 shows that COPD patients have signiﬁcantly higher
level of ANA and ASMA than in the control group.
Table 6 shows that group B patients have signiﬁcantly high-
er levels of ANA and ASMA than both group A and healthy
smokers (group C) and non smokers (group D). Healthy
smokers (group C) have both ANA and ASMA signiﬁcantly
higher than group A patients and non smokers (group D).
Table 7 shows that there is a non signiﬁcant relation of
patient’s main symptoms to the level of ANA.
Table 8 shows that there is a non signiﬁcant relation of
patient’s main symptoms to the level of ASMA.
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52 T.M. Gouda et al.Discussion
In the present study, although our patients were randomly se-
lected according to the inclusion and exclusion criteria, all patients
were males (100%) (Table 1) indicating a higher prevalence of the
disease among males and this is concordant with the COPD liter-
ature in which higher prevalence of the disease among males is
well known [8]. The higher prevalence of the disease in males
may be largely related to the higher rate of smoking and occupa-
tional exposure to pollution among men [20].
In a large multicenter study created by Caillaud et al. [6]
that included 591 COPD patients it was found that 80.7%
were males who were smokers or ex smokers exposed to differ-
ent vapors and fumes at work place. The authors concluded
that, occupational exposure is an independent risk factor for
COPD whatever the smoking status of the patients.
Although females are more susceptible to the effect of to-
bacco smoke than males [26], yet the higher prevalence was
seen among males as indicated by absence of females in the pa-
tients. Again this is mostly due to factors mentioned above
plus a lower incidence of smoking among females in our coun-
try due to social, economic and religious factors [23].
In this work levels of ANA and ASMA were found to be
higher in COPD patients compared to controls (smokers and
non smokers) and the difference between them was statistically
signiﬁcant (p= 0.001) (Table 2).
This result agrees with Bonarius et al. [5], who measured
serum levels of autoantibodies, anti nuclear antibody (ANA)
and anti tissues antibody (ATA) including ASMA in a total
232 subjects, 124 patients with COPD (94 smokers and 30
non smokers) plus 108 control subjects (71 smokers and 37
non smokers) in whom age and gender were matched. In these
four subject groups they found seropositivity for ANA to be
higher among COPD patients (44%) than controls (22%)
and the difference was statistically signiﬁcant (p= 0.001).
ASMA were measured in only 12 of the studied patients and
all samples were negative. The negative ASMA in these pa-
tients disagrees with our results and this discrepancy could
be explained by the low number of ASMA assessed patients
or a different degree of smoking severity.
The result also agrees with [10] who reported that 32 of 47
patients with COPD (68%) were serum positive for ANA.
Also, Hodson and Turner-Warwick [16] found 28% of 50 pa-
tients with severe chronic bronchitis to be serum positive for
ANA and were signiﬁcantly higher than that found in age
and sex matched non bronchitic controls (4%) which are in
support of this study ﬁndings.
In a study done by Nunez et al., [22] who measured serum
titers of ANA and anti tissue antibodies by immunoﬂuores-
cence in 328 patients with clinically stable COPD and in 67
healthy controls (31 smokers and 36 non smokers), it was
found that 34% of patients had high ANA titer (>1:160), ele-
ven times higher than that seen in the control group (3%).
They found that 11% of COPD patients had ANA titer
(>1:320) which was too high.
Also Nunez et al., [22] found that 26% of studied COPD
patients showed high ATA titers (>1:160) with 4.5 times
higher prevalence than controls (6%), more over 21% of their
patients showed very high ATA titers (>1:320) with ASMA
sero-positivity found in most of ATA positive patients
(n= 80). Results of Nunez et al. [22] support our ﬁndings.
Table 4 Correlation between levels of ANA, ASMA (Units/
ml) and post bronchodilator FEV1% in the whole group of
COPD patients.
Pearson correlation P value Signiﬁcance
Post FEV1%
ANA -0.693 0.001 *S
ASMA -0.637 0.001 *S
* S = signiﬁcant.
Table 2 Comparison of smoking index among COPD patients (Group A and B) and apparently healthy smokers (Group C).
Groups Mean ±SD Range F test P value
Smoking index Group A 415.0 242.94 140–800 4.82 0.011*S
Group B 697.8 433.3 200–2000
Healthy smokers 670.0 323.38 250–1500
* S = signiﬁcant.
Table 3 Comparison of levels of ANA and ASMA (Units/ml) between Group A and Group B COPD patients.
Variable Groups Mean ±SD Student t test P value
ANA (units/ml) Group A 33.5 21.5 6.61 0.001 S*
Group B 73.86 21.65
ASMA (units/ml) Group A 25.32 8.41 5.144 0.001 S*
Group B 40.65 12.31
* S = signiﬁcant.
Study of anti nuclear and anti smooth muscle antibodies 53Barcelo et al. [3] found that patients with chronic obstruc-
tive pulmonary disease showed increased percentages of
CD8+ T-lymphocytes, which is consistent with a ﬁnal matura-
tion activation state of these cells with a correspondingly high-
er potential for tissue injury, further supporting a potential
involvement of the acquired immune response in the pathogen-
esis of chronic obstructive pulmonary disease.
In this study it was found that the levels of ANA and
ASMA were related to the stage of the disease as there was a
signiﬁcant increase in ANA and ASMA levels with increasing
the severity of COPD, as severe and very severe COPD cases
(group B) showed higher levels of ANA and ASMA than mild
and moderate cases (group A), and the difference between
them was statistically signiﬁcant (P= 0.001) (Table 3).
Hogg [17] showed that the progression of COPD (from
GOLD stage 0 to GOLD stage 4) was associated with in-
creased production of mucus in the lumen of peripheral air-
ways, thickening of the airway wall and ampliﬁcation of the
inﬂammatory response, mainly due to the accumulation of
CD8+ T-cells and, interestingly, B-cells which are responsible
for the secretion of antibodies. Moreover they found that, in
patients with the most severe stages of COPD, inﬂammatory
cells in the airway wall organize into lymphoid follicles to facil-
itate antigen presentation to the cells of the adaptive immune
response. The authors suggested that these follicles represent
an adaptive immune response which may develop in relation
to microbial colonization and infection occurring in the later
stages of COPD.
The data regarding involvement of B-cells have been re-
cently supported by the observation that these cells are also in-
creased in biopsies of bronchi from patients with increasing
severity of COPD [14]. Another observation of increased num-
bers of plasma cells (i.e. end-stage differentiated B-cells) in and
around the mucus secreting glands of patients with chronic
bronchitis had been reported by Jeffery and Zhu [19]. Further-
more, in a recent study in human COPD lung and smoking
mouse lung models, B-cell follicles were found to be present
also in the parenchyma (Van der Strate et al. [28]). The authors
had also demonstrated that parenchymal follicular B-cells in
human COPD patients to be of oligoclonal origin, supporting
B-cells in COPD to accumulate as a result of speciﬁc antigenic
stimulation. Apart from microbial antigens, cigarette smokeparticles or degradation products of lung extracellular matrix
may also be the antigenic drive to such B-cell development
[1]. Activation of CD8+ T lymphocytes and expansion of
B-cells suggest a role in autoimmunity in COPD [1].
Contrary to this study results, Bonarius et al. [5] found that
within the COPD studied group there was no association be-
tween ANA level and COPD stages as deﬁned by GOLD
(2009) [13] criteria. Also this result is not in agreement with
[10] who suggested that an autoimmune response is associated
with having developed COPD as such and not with the severity
of the disease.
Nunez et al. [22] found that 21% of COPD patients with
positive ASMA have levels inversely related to lung function
impairment (p= 0.05). They explained this by airway remod-
eling in COPD patients as airway smooth muscle cells can syn-
thesize extracellular matrix protein and downregulate matrix
metalloproteinases. It is possible that attacking smooth muscle
with autoantibodies will disturb their physiology and can en-
hance production of harmful substances by these cells.
As regards the relation between both ANA and ASMA lev-
els and pulmonary function tests, this study showed a signiﬁ-
cant negative correlation between both antibodies and post
bronchodilator FEV1% pred in the whole COPD group indi-
cating that both ANA and ASMA in some way have a role in
the pathology underlying airway dysfunction in these patients
(Table 4).
This result agrees with Nunez et al. [22] for ASMA but not
for ANA. These authors demonstrated a negative correlation
between airway function and ASMA but could not ﬁnd this
relation with ANA. Also Greene et al. [15] found serum
Table 6 Comparison of ANA and ASMA levels (Units/ml)
between both patient groups and healthy smoker controls and
non smokers.
Variable (n= 65) Mean ±SD F test P value
ANA
Group A 33.5 21.5 30.47 0.001 S*
Group B 73.86 21.65
Healthy smokers (gp C) 51.59 31.66
Healthy non smokers (gp D) 9.33 2.54
ASMA
Group A 25.32 8.41 30.9 0.001 S*
Group B 40.65 12.31
Healthy smokers 30.19 14.85
Healthy non smokers 7.52 3.96
* S = signiﬁcant.
Table 5 Comparison of ANA and ASMA levels (Units/ml) in COPD as a whole (50 patients) and controls (30 patients).
Variable Groups Mean ±SD Student t test P value
ANA (units/ml) COPD 53.68 29.52 3.35 0.001 *S
Control 30.46 30.81
ASMA (units/ml) COPD 32.98 12.99 *3.86 0.001 *S
Control 18.86 15.72
* S = signiﬁcant.
54 T.M. Gouda et al.concentrations of anti tissue antibodies (especially antismooth
muscle antigen antibodies), to be present in a ﬁfth of patients
with COPD, and correlated with the severity of airﬂow limita-
tion. On the other hand Bonarius et al. [5] found no relation
between both antibodies and lung function impairment.
Although ANA is found to be prevalent in COPD patients,
Wood et al. [30] could not ﬁnd a relation between them and
smoking status or FEV1.
In this work levels of ANA and ASMA were found to be
higher in COPD patients compared to controls (smokers andTable 7 Relation between level of ANA (Units/ml) and clinical sym
ANA Negative(<20) Moderate positive(20–60) S
No % No % N
Clinical symptoms
Cough 4 36.4 6 35.3 8
Dyspnea 7 63.6 11 64.7 1
Total 11 100 17 100 2
* NS = non signiﬁcant.
Table 8 Relation between level of ASMA (Units/ml) and clinical s
ASMA Negative(<20) Week positive(20–30) Moderate to
No % No % No
Clinical symptoms
Cough 3 100 7 31.8 8
Dyspnea 0 0.0 15 68.2 17
Total 3 100 22 100 25
* NS = non signiﬁcant.non smokers) and the difference between them was statistically
signiﬁcant (p= 0.001) (Table 5).
This result agrees with Bonarius et al. [5], who measured
serum levels of autoantibodies, anti nuclear antibody (ANA)
and anti tissue antibody (ATA) including ASMA in a total
232 subjects, 124 patients with COPD (94 smokers and 30
non smokers) plus 108 control subjects (71 smokers and 37
non smokers) in whom age and gender were matched. In these
four subject groups they found seropositivity for ANA to be
higher among COPD patients (44%) than controls (22%)
and the difference was statistically signiﬁcant (p= 0.001).
ASMA were measured in only 12 of studied patients and all
samples were negative. The negative ASMA in these patients
disagrees with our results and this discrepancy could be ex-
plained by the low number of ASMA assessed patients or a dif-
ferent degree of smoking severity.
The result also agrees with [10] who reported that 32 of 47
patients with COPD (68%) were serum positive for ANA.
Also, Hodson and Turner-Warwick [16] found 28% of 50 pa-
tients with severe chronic bronchitis to be serum positive for
ANA and were signiﬁcantly higher than that found in age
and sex matched non bronchitic controls (4%) which are in
support of this study ﬁndings.
In a study done by Nunez et al., [22] who measured serum
titers of ANA and anti tissue antibodies by immunoﬂuores-
cence in 328 patients with clinically stable COPD and in 67
healthy controls (31 smokers and 36 non smokers), it wasptoms in COPD patients.
trong positive(>60) Total Fischer exact
test
P value
o % No %
36.4 18 36.0 0.103 1.0 NS*
4 63.6 32 64.0
2 100 50 100
ymptoms in COPD patients.
strong positive(>30) Total Fischer exact test P value
% No %
32.0 18 36.0 4.93 0.089 NS*
68.0 32 64.0
100 50 100
Study of anti nuclear and anti smooth muscle antibodies 55found that 34% of patients had high ANA titer (>1:160), ele-
ven times higher than that seen in control group (3%). They
found that 11% of COPD patients had ANA titer (>1:320)
which was too high.
Also Nunez et al., [22] found that 26% of studied COPD
patients showed high ATA titers (>1:160) with 4.5 times
higher prevalence than controls (6%), more over 21% of their
patients showed very high ATA titers (>1:320) with ASMA
sero-positivity found in most of ATA positive patients
(n= 80). Results of Nunez et al. [22] support our ﬁndings.
Barcelo et al. [3] found that patients with chronic obstruc-
tive pulmonary disease showed increased percentages of
CD8+ T-lymphocytes, which is consistent with a ﬁnal matura-
tion activation state of these cells with a correspondingly high-
er potential for tissue injury, further supporting a potential
involvement of the acquired immune response in the pathogen-
esis of chronic obstructive pulmonary disease.
Concerning ANA and ASMA levels, the mean values of
ANA and ASMA in group B patients were signiﬁcantly higher
than in group A patients and healthy smokers and healthy non
smokers. Healthy smokers have ANA and ASMA mean values
signiﬁcantly higher than group A patients and healthy non
smokers (group D) and the difference between them was statis-
tically signiﬁcant (P= 0.001) (Table 6).
These ﬁndings are similar to the those of Bonarius et al. [5],
who found seropositivty for ANA to be higher among smoker
COPD (40 of 94) than control smokers (17 of 71) and the dif-
ference was statistically signiﬁcant (p= 0.013).
In this work, levels of ANA and ASMA were found to be sig-
niﬁcantly higher in patients with dyspnea as the main symptom
than in those with cough (Table 7 and 8). This indicates that
these antibodies are either associated with disease severity which
is mainly judged from patient disability due to dyspnea [4], or re-
lated to parenchymal injury manifested clinically and radiologi-
cally by emphysema and/or vascular injury (pulmonary
hypertension). This issue needs a separate work to evaluate.
This result agrees with Bonarius et al. [5] who found that
emphysematous phenotype COPD patients (with low attenua-
tion areas on CT scan) have higher levels of ANA. Also Lee
et al., [21] demonstrated the presence of antielastin antibodies
and Th1 responses in patients with COPD, which were corre-
lated with severity of emphysema.
Also this result is supported by the work of van der Strate
et al. [28] who found lymphoid follicles consisting of B-cells
and follicular dendritic cells (DCs) with adjacent T-cells to
be present both in parenchyma and bronchial walls of patients
with emphysema plus an oligoclonal antigen-speciﬁc reaction
of the B-cells a ﬁnding commonly seen in autoimmune disor-
ders. Also Sullivan et al. [27] have shown the presence of
CD4+ T-lymphocyte in oligoclonal expansion in the lungs
of patients with severe emphysema
Conﬂict of interest
None declared.References
[1] A. Agusti, W. MacNee, K. Donaldson, M. Cosio, Hypothesis:
does COPD have an autoimmune component?, Thorax 58
(2003) 832–834[2] P. Anderson, Studies on the speciﬁcity of smooth-muscle
antibodies, Clin. Exp. Immunol. 26 (1976) 57–66.
[3] B. Barcelo, J. Pons, J.M. Ferrer, J. Sauleda, I.A. Fuster, A.G.N.
Agusti, et al, Eur. Respir. J. 31 (2008) 555–562.
[4] J.C. Bestall, E.A. Paula, R.R. Garroda, J.A. Wedzichaa,
Usefulness of the Medical Research Council (MRC) dyspnoea
scale as a measure of disability in patients with chronic
obstructive pulmonary disease, Thorax 54 (7) (1999) 581–586.
[5] H.P.J. Bonarius, C.A. Brandsma, H.A.M. Kerstjens, J.A.
Koerts, M. Kerkhof, E. Nizankowska-Mogilnicka, et al,
Antinuclear autoantibodies are more prevalent in COPD in
association with low body mass index but not with smoking
history, Thorax 66 (2011) 101–107.
[6] D. Caillaud, F. Lemoignef, P. Carre, R. Escamilland, P. Chanez,
R. Burgelp, et al, The association between occupational
exposure and the clinical characteristics of COPD, BMC
Public Health 12 (2012) 302.
[7] M.G. Cosio, M. Saette, A. Agusti, Immunologic aspects of
chronic obstructive pulmonary disease, N. Engl. J. Med. 360
(2009) 2445–2454.
[8] P. Cullinan, Persistent cough and phlegm: prevalence and
clinical characteristics in south-east England, Respir. Med. 86
(1992) 143.
[9] R. Doll, R. Peto, Cigerrate smoking and bronchial carcinoma:
dose and time relationship among regular smokers and life long
non smokers, J. Epidemiol. Community Health 32 (1978) 303–
313.
[10] C.A. Feghali-Bostwick, A.S. Gadgil, L.E. Otterbein, J.M.
Pilewski, M.W. Stoner, E. Csizmadia, Y. Zhang, et al,
Autoantibodies in patients with chronic obstructive pulmonary
disease, Am. J. Respir. Crit. Care. Med. 177 (2008) 156–163.
[11] F. Ferna´ndez-Madrid, R.L. Karvonen, M.J. Kraut, B.
Czelusniak, J.W. Ager, Autoimmunity to collagen in human
lung cancer, Cancers Res. 56 (1996) 121–126.
[12] J. Garcia-Aymerich, F.P. Gomez, J.M. Anto, Phenotypic
characterization and course of chronic obstructive pulmonary
disease in the PAC-COPD Study: design and method, Arch.
Bronconeumo. 45 (2009) 4–11.
[13] Global Initiative for Chronic Obstructive Lung Disease, Global
strategy for the diagnosis, management and prevention of
chronic obstructive pulmonary disease. (2009), NHLBI/WHO
Global Initiative for Chronic Obstructive Lung Disease
(GOLD).
[14] M.M. Gosman, B.W. Willemse, D.F. Jansen, et al, Increased
numbers of B-cells in bronchial biopsies in COPD: Eur, Respire.
J. 27 (2006) 60–64.
[15] C.M. Greene, T.B. Low, S.J. O’Neill, N.G. McElvaney, Anti-
proline-glycine-proline or antielastin autoantibodies are not
evident in chronic inﬂammatory lung disease, Am. J. Respir.
Crit. Care. Med. 181 (2010) 31–35.
[16] M.E. Hodson, M. Turner-Warwick, Autoantibodies in patients
with chronic bronchitis, Br. J. Dis. Chest 70 (1976) 83–88.
[17] J. Hogg, Pathophysiology of airﬂow limitation in chronic
obstructive pulmonary disease, Lancet 364 (9435) (2004) 709–
721.
[18] T. Ichijo, K. Kiyosawa, Hepatitis C virus infection and
autoimmunity, J. Gastroentrol. Hepatol. 17 (2002) 813–815.
[19] P.K. Jeffery, J. Zhu, Mucin-production elements and
inﬂammatory cells. Novartis Found, Symposium, 248 (2002)
51-68.
[20] O.P. Kurmi, S. Semple, P. Simkhada, W.C. Smith, J.G. Ayres,
COPD and chronic bronchitis risk of indoor air pollution from
solid fuel: a systematic review and meta-analysis, Thorax 65 (3)
(2010) 221–228.
[21] S.H. Lee, S. Goswami, A. Grudo, L.Z. Song, V. Bandi, S.
Goodnight- White, Antielastin autoimmunity in tobacco
smoking-induced emphysema, Nat. Med. 13 (2007) 567–569.
56 T.M. Gouda et al.[22] B. Nunez, J. Sauleda, J.M. Anto, Anti-tissue antibodies are
related to lung function in chronic obstructive pulmonary
disease, Am. J. Respir. Crit. Care Med. 183 (2010) 1025–1031.
[23] F.C. Pampel, Global patterns and determinents of sex
differences in smoking, Int. J. Comp. Sociol. 47 (6) (2006)
466–487.
[24] R. Pellegrino, G. Viegi, V. Brusasco, Interpretative strategies for
lung function tests, Eur. Respir. J. 26 (2005) 948–968.
[25] A. Sawalha, A. Harley, Antinuclear autoantibodies in systemic
lupus erythematous, Curr. Opin. Rheumatol. 16 (2004) 534–540.
[26] I.C. Sorheim, A. Johannessen, A. Gulsvik, P.S. Bakke, E.K.
Silverman, D.L. Demeo, et al, Gender difference in COPD: are
women more susceptible to smoking effects than men?, Thorax
65 (6) (2010) 480–485[27] A.K. Sullivan, P.L. Simonian, M.T. Falta, Oligoclonal CD4+ T
cells in the lungs of patients with severe emphysema, Am. J.
Respir. Crit. Care Med. 172 (2005) 590–596.
[28] B.W. Van der Strate, D.S. Postma, C.A. Brandsm, Cigarette
smoke-induced emphysema: a role for the B cell, Am. J. Respir.
Crit. Care Med. 173 (2006) 751–758.
[29] C.A. VonMuhlen, E.M. Tan, Autoantibodies in the diagnosis of
systemic rheumatic diseases, Semin Arthritis. Rheum. 24 (1995)
323–358.
[30] A.M. Wood, P. de Pablo, C.D. Buckley, A. Ahmad, R.A.
Stockley, Smoke exposure as a determinant of autoantibody
titre in alpha1-antitrypsin deﬁciency and COPD, Eur. Respir. J.
37 (2011) 32–38.
